Kangfang confirms that the medical representative forged materials to obtain cancer drugs through deception.

The distribution of anti-tumor drugs labeled "for clinical research use only" from Kangfang Biotech to patients has attracted attention. Kangfang Biotech stated that their sales personnel in Chongqing obtained a certain quantity of drugs from the company by forging research approval documents and hospital ethics approval materials, under the guise of conducting post-market clinical research initiated by researchers. Kangfang is currently cooperating with relevant regulatory authorities to investigate this incident. This incident involves Kangfang, pharmaceutical representatives, hospitals, doctors, and patients, and further responsibility identification is pending the regulatory authorities' decision.